InsidersTradesSigma
Follow the 리메드 stock price and the full management transaction log of the company, a listed equity based in South Korea. Shares are listed on the KR market, under the authority of DART (FSS). Operating in the Health Care sector, 리메드 has logged 10 reports. Market capitalisation: €83bn. The latest transaction was disclosed on 4 May 2026 (Other). Among the most active insiders: 이근용. The full history is openly available.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
10 of 10 declarations
리메드 活跃于医疗保健和制药领域，在 XKRX 市场上市。该公司专注于开发创新的医疗保健解决方案。